Indivior (United States)

Recent papers from Indivior (United States)

1. Rocavorexant, a novel, selective orexin‐1 receptor antagonist: Safety, tolerability and pharmacokinetics in healthy adults and individuals with opioid use disorderBritish Journal of Clinical Pharmacology · 2026
2. FRAUD-X: An explainable AI-based deep learning model for real-time cloud-driven financial fraud and risk analysisAfrican Journal of Science Technology Innovation and Development · 2026
3. Safety Evaluation of Intranasal Nalmefene in Juvenile Rat Studies in Support of Clinical Trials in Pediatric Patients From Birth to 12 Years of AgeInternational Journal of Toxicology · 2026
4. Assessing impact of buprenorphine for opioid use disorder on infectious disease management.2026
5. Surveying Correctional Health Staff on Medication for Opioid Use Disorder Diversion: Barriers and Mitigation StrategiesJournal of Correctional Health Care · 2026
6. Relationship Between Extended-Release Buprenorphine Adherence and Relapse Reduction in Patients with Opioid Use Disorder: A Retrospective Claims Data AnalysisDrug and Alcohol Dependence Reports · 2026
7. Association between extended-release buprenorphine adherence and reduced healthcare costs among insured patients with opioid use disorderFrontiers in Public Health · 2026
8. Medications for Opioid Use Disorder in Correctional Facilities: A 2022 Cross-Sectional Survey of Health Care StaffJournal of Correctional Health Care · 2026
9. Accurate quantification of steps from multiple smartphone positionsScientific Reports · 2026
10. Comparison of Extended-Release Buprenorphine Doses for Treating High-Risk Opioid UseJAMA Network Open · 2025
11. Online product decision support using review analysis and Transformer-GRU hybrid model through e-commerce platformJournal of Strategic Marketing · 2025
12. Response to: improvements to out-of-hospital cardiac arrest and opioid overdose treatment algorithms to enhance positive outcomesEmergency and Critical Care Medicine · 2025
13. Post-marketing Surveillance of Intranasal Nalmefene: Prevalence and Clinical Relevance of Precipitated WithdrawalCureus · 2025
14. Rapid vs Standard Induction to Injectable Extended-Release BuprenorphineJAMA Network Open · 2025
15. Reversal of a synthetic opioid overdose: Insights from a validated translational modelNeuropharmacology · 2025
16. Factors associated with emergency room visits among patients with opioid use disorder: A study of buprenorphine-treated and untreated patientsDrug and Alcohol Dependence Reports · 2025
17. Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment responseNeuropsychopharmacology · 2025
18. Monthly buprenorphine depot injection (SUBLOCADE®) for opioid use disorder during pregnancyAmerican Journal on Addictions · 2025
19. Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit MessagesJournal of Medical Internet Research · 2025
20. Translational Modeling as a Tool to Evaluate the Effectiveness of Nalmefene in a Community Setting: A Critical PerspectiveClinical Pharmacology & Therapeutics · 2025